There will be flight cancellations ‘soon’ if oil supplies are not restored in coming weeks, says head of IEA Business live – latest updates Middle East crisis – live updates Europe has only six weeks’ supply of jet fuel left before shortages will hit because of the Iran war, according to the head of a global energy watchdog. Fatih Birol, the head of the International Energy Agency (IEA), said ther...
There will be flight cancellations ‘soon’ if oil supplies are not restored in coming weeks, says head of IEA Business live – latest updates Middle East crisis – live updates Europe has only six weeks’ supply of jet fuel left before shortages will hit because of the Iran war, according to the head of a global energy watchdog. Fatih Birol, the head of the International Energy Agency (IEA), said there will be flight cancellations “soon” if oil supplies from the Middle East are not restored within the coming weeks. Continue reading...
Key PointsThough the S&P 500 and iShares Expanded Tech-Software Sector ETF have historically moved in tandem, they're currently 2% and 37% below their all-time highs, respectively.
Key PointsThough the S&P 500 and iShares Expanded Tech-Software Sector ETF have historically moved in tandem, they're currently 2% and 37% below their all-time highs, respectively.
S&P 500 Index futures rise 0.1% as of 7:51 a.m. in New York as an upbeat forecast from TSMC lifts technology shares. Nasdaq 100 futures rise 0.2% Dow Jones Industrial Average futures are up 0.1% The MSCI World Index is up 0.1% Here are some of the biggest US movers before the bell: Magnificent Seven stocks: Microsoft (MSFT) +1.3%, Tesla (TSLA) +0.7%, Meta Platforms (META) +0.5%, Nvidia (NVDA) -0.4...
S&P 500 Index futures rise 0.1% as of 7:51 a.m. in New York as an upbeat forecast from TSMC lifts technology shares. Nasdaq 100 futures rise 0.2% Dow Jones Industrial Average futures are up 0.1% The MSCI World Index is up 0.1% Here are some of the biggest US movers before the bell: Magnificent Seven stocks: Microsoft (MSFT) +1.3%, Tesla (TSLA) +0.7%, Meta Platforms (META) +0.5%, Nvidia (NVDA) -0.4%, Alphabet (GOOGL) -0.2%, Apple (AAPL) +0.8%, Amazon (AMZN) -0.1% Nuclear and uranium companies are set to extend this week’s rally after the White House released rules for establishing a National Initiative for American Space Nuclear Power. Oklo (OKLO) +7%, NuScale Power (SMR) +10%. Quantum computing shares are on track to extend gains for a third consecutive session after Nvidia unveiled a suite of new open-source AI models aimed at accelerating progress within quantum computing. Allbirds (BIRD) tumbles 21% as the newly minted AI stock takes a breather after soaring more than 580% on Thursday. Hims & Hers (HIMS) rises 9%, with shares on track to extend the previous day’s 14% rally, after Health Secretary Robert F. Kennedy Jr. said the FDA is seeking to remove 12 peptides from Category 2 restrictions. PepsiCo Inc. (PEP) gains 1% after quarterly revenue and earnings beat expectations as the maker of Doritos and Lay’s sees improvement in salty snacks volume following recent price cuts. PPG Industries (PPG) rises 3% after the supplier of paints and coatings posted preliminary first quarter adjusted earnings per share that topped expectations. QuidelOrtho Corp. (QDEL) sinks 17% after the health care services provider posted disappointing preliminary first-quarter revenue as US flu-like illness visits fell by about 30% from the year-earlier period. Travelers (TRV) slips 1.4% after the insurance company posted first quarter results where net premiums written declined 1.7% from the year-ago period. U.S. Bancorp (USB) rises about 1% after first-quarter profit beat estimates, as C...
*Other Operating Data Consensus Source: Bloomberg More on Abbott Laboratories Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles Abbott Laboratories Non-GAAP EPS of $1.15 in-line, revenue of $11.16B beats by $160M ...
*Other Operating Data Consensus Source: Bloomberg More on Abbott Laboratories Abbott Laboratories: A Dividend Aristocrat With A Compelling Valuation And Return Potential Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles Abbott Laboratories Non-GAAP EPS of $1.15 in-line, revenue of $11.16B beats by $160M Abbott seen posting modest Q1 earnings amid Nutrition segment slowdown
In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT Eli Lilly Foundayo GLP-1 weight loss pill. Courtesy: Eli Lilly Eli Lilly said on Thursday its newly approved obesity pill helped reduce the risk of major cardiovascular events at a similar rate as insulin glargine in adults with type 2 diabetes and obesity, meeting the main goal of a long late-stage trial. In the study of more tha...
In this article LLY Follow your favorite stocks CREATE FREE ACCOUNT Eli Lilly Foundayo GLP-1 weight loss pill. Courtesy: Eli Lilly Eli Lilly said on Thursday its newly approved obesity pill helped reduce the risk of major cardiovascular events at a similar rate as insulin glargine in adults with type 2 diabetes and obesity, meeting the main goal of a long late-stage trial. In the study of more than 2,700 adults, patients taking Foundayo had a 16% lower risk of heart attack, stroke or cardiovascular death, and a 57% lower risk of death from any cause compared with those on insulin glargine. Patients taking Foundayo also saw bigger drops in blood sugar and weight after a year, while those on insulin glargine gained weight, the company said. Lilly said it will seek U.S. approval of Foundayo for type 2 diabetes under the Commissioner's National Priority Review Voucher, and will submit an application for it by the end of the second quarter. Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
RHJ/iStock via Getty Images Americas Gold and Silver ( USAS ) up 1.4% pre-market Thursday after saying Q1 consolidated silver production surged 76% Y/Y to a company record 787K oz, while the company sold a record 830K oz due to a positive adjustment for timing of concentrate sales. Consolidated Q1 production of lead totaled 2M lbs, copper output came in at 967K lbs, and antimony production amassed...
RHJ/iStock via Getty Images Americas Gold and Silver ( USAS ) up 1.4% pre-market Thursday after saying Q1 consolidated silver production surged 76% Y/Y to a company record 787K oz, while the company sold a record 830K oz due to a positive adjustment for timing of concentrate sales. Consolidated Q1 production of lead totaled 2M lbs, copper output came in at 967K lbs, and antimony production amassed 137K lbs. Americas Gold and Silver ( USAS ) said it is on schedule to complete Phase 2 upgrades to the No. 3 shaft at Galena, which will increase skipping speeds to ~105 short tons per hour; the upgrades will be completed during a planned two-week shutdown during the quarter. The company said the upgrade will boost ore hoisting capability in the No. 3 shaft, a significant step forward for operations at Galena as it continues to ramp up tonnage resulting from the transition to long hole stoping. More on Americas Gold and Silver Americas Gold and Silver Q4 2025 Earnings Call Transcript Americas Gold and Silver: The Market Is Looking At 2026, Not 2025 Financial information for Americas Gold and Silver
OpenAI ( OPENAI ) is trying to deepen the use of artificial intelligence in the life sciences, according to a new research paper published by the company. While noting that the 20th century was a century of discovery and saving countless lives, OpenAI's researchers noted that progress has slowed down. Drug development costs are nearly doubling every nine years; clinical trials are taking roughly 7...
OpenAI ( OPENAI ) is trying to deepen the use of artificial intelligence in the life sciences, according to a new research paper published by the company. While noting that the 20th century was a century of discovery and saving countless lives, OpenAI's researchers noted that progress has slowed down. Drug development costs are nearly doubling every nine years; clinical trials are taking roughly 7.5 years on average to complete; and diseases such as cancer, heart disease, stroke, diabetes, and more still account for roughly 74% of all deaths globally. And that is where AI comes in, according to the researchers. “AI is beginning to jumpstart that progress, with approximately 200,000 global weekly users – from the United States and Great Britain, to India and South Korea – already relying on ChatGPT for advanced life sciences work that helps researchers integrate knowledge and translate across the disciplinary gaps that act as barriers to discovery,” the researchers wrote in the paper. They continued: “These users include a seemingly terminal patient who used ChatGPT to outpace his rare cancer while processing massive amounts of personal data to identify experimental treatments; rare-disease families that have used ChatGPT to go beyond their diagnostic odyssey and surface possible treatments, communities, and experts; and AI-native startups that have built lean platforms for novel drug candidates.” The researchers pointed to Eroom's Law, which is Moore's Law in reverse. They noted that scientific research has slowed as more knowledge is gained. “The slowdown in life-science progress is not confined to pharmaceuticals. Bloom et al showed that across industries, research effort keeps rising while per-researcher productivity falls sharply,” the researchers explained. “U.S. research productivity has declined 41-fold since the 1930s. The reason is structural. As knowledge accumulates, each generation of scientists must spend more time training, only to specialize more narr...
Jeremy Edwards The Trump administration signaled this week that Federal Reserve Chair Jerome Powell should not remain in his role past May 15, when his term expires, without a confirmed successor, setting up a potential legal showdown with the central bank over who holds authority to appoint interim leadership. Now, here are the key developments to watch from The Wall Street Journal: The May 15 de...
Jeremy Edwards The Trump administration signaled this week that Federal Reserve Chair Jerome Powell should not remain in his role past May 15, when his term expires, without a confirmed successor, setting up a potential legal showdown with the central bank over who holds authority to appoint interim leadership. Now, here are the key developments to watch from The Wall Street Journal: The May 15 deadline looms: Fed Chair Jerome Powell’s term is set to expire without a confirmed successor in place, creating an unprecedented vacancy scenario at the top of the nation’s central bank during a period of significant economic uncertainty and ongoing monetary policy deliberations. Administration draws hard line: The White House has made clear its position that Powell should not continue serving as chair beyond the expiration date, marking a sharp escalation in the long-standing tension between President Trump and the Fed chief he initially appointed during his first term. Bessent names alternatives: Treasury Secretary Scott Bessent publicly floated Vice Chair Philip Jefferson and Governor Christopher Waller as potential interim leaders, signaling the administration is actively preparing contingency plans and may seek to install its preferred choice rather than allow Powell to remain. Legal ambiguity at center stage: The law does not clearly specify what happens when a Fed chair’s term expires without a confirmed successor, leaving open a critical question: Does the White House or the Federal Reserve itself hold the authority to determine interim leadership arrangements? Institutional clash brewing: The White House and the Federal Reserve hold fundamentally different interpretations of succession authority, raising the prospect of a constitutional confrontation that could test the boundaries of central bank independence and unsettle financial markets. Dear readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to...
Curaleaf ( CURLF ) plans to commence a normal course issuer bid to repurchase up to 34,388,831 of its subordinate voting shares, representing ~5% of the subordinate voting shares issued and outstanding as of April 10, 2026. The program will run from April 20, 2026, through April 19, 2027. Source: Press Release More on Curaleaf Holdings, Inc. Curaleaf: Not Reaching For A Mixed Bag Curaleaf Benefits...
Curaleaf ( CURLF ) plans to commence a normal course issuer bid to repurchase up to 34,388,831 of its subordinate voting shares, representing ~5% of the subordinate voting shares issued and outstanding as of April 10, 2026. The program will run from April 20, 2026, through April 19, 2027. Source: Press Release More on Curaleaf Holdings, Inc. Curaleaf: Not Reaching For A Mixed Bag Curaleaf Benefits From International Expansion While The Cannabis Sector Remains Weak Curaleaf Holdings, Inc. (CURA:CA) Q4 2025 Earnings Call Transcript Curaleaf to refinance debt with $500 million senior secured notes offering Curaleaf expects Q4 revenue of $330M